Company intelligence / Profile preview

Vaxxilon AG

Reinach BL, Basel-Landschaft, Switzerlandmpg.de ↗

Ownership: Private
Development stage: Preclinical

Overview

Vaxxilon AG specialized in developing innovative synthetic carbohydrate-based vaccines primarily targeting bacterial infections. The company held exclusive rights to several preclinical vaccine candidates aimed at pathogens with unmet medical needs. Its technology promised improved stability, easier transport/storage, and lower costs compared to traditional vaccines. As of its acquisition by Idorsia, all programs remained preclinical with plans for future clinical trials but no reported results yet.

Therapeutic areas: OtherInfectious Diseases
Modalities: Synthetic carbohydrate vaccines
Industry: Biotech

Drug pipeline

1 asset

VXN-319

Pre-clinical

Indications: Klebsiella pneumoniae infections

Partnerships

Actelion Ltd.Max Planck Society / Max Planck Innovation GmbH

Beyond the preview

Go deeper on Vaxxilon AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxxilon AG.

Explore the full profile